ARCHIVES

Study Finds 4-20% Of Those With HTLV-3 Develop AIDs Within 32 Months Or Less

This article is from The Cancer Letter archive.

Vol. 11 No. 31 | August 2, 1985

Download PDF Visit The Full Archive

Related Articles

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011

Approvals and Applications: European Committee Signs Off On Paxene for KS reatment

March 5, 1999

Zometa Reduced Bone Complications In Patients With Prostate Cancer Bone Mets

October 25, 2002

100 NSABP Sites May Enroll Patients; Only One Trial Open

July 15, 1994

In Brief: Congressional Action Imminent On Cancer Ac Renewal, Hew Money Bills; Veto Threatened

September 8, 1978

Gallo, Four Others Share Lasker Award

November 19, 1982